Apellis Pharma director Dunlop A. Sinclair sells $737k in APLS

Published 16/10/2025, 01:20
Apellis Pharma director Dunlop A. Sinclair sells $737k in APLS

Director Dunlop A. Sinclair of Apellis Pharmaceuticals Inc (NASDAQ:APLS), a biotech company with a market capitalization of $3.17 billion, recently sold 31,092 shares of common stock on October 10, 2025, for a total of $737,536. The shares were sold at weighted average prices ranging from $23.47 to $23.93, below the current trading price of $25.24. According to InvestingPro analysis, APLS shows signs of being slightly undervalued, with the stock posting an impressive 38.88% return over the past six months.

The transaction was executed indirectly through Epidarex, with Sinclair being a general partner and potentially having voting and dispositive power over the shares. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex on June 20, 2025.

On June 24, 2025, Sinclair also transferred 4,787 shares of Apellis Pharmaceuticals common stock to Epidarex Capital I LP for no consideration. Additionally, 3,837 shares were distributed from Epidarex to a Limited Partner and General Partner of Epidarex, also for no consideration.

In other recent news, Apellis Pharmaceuticals reported its second-quarter 2025 earnings, revealing a revenue of $178 million. This financial update highlights the company’s growth in revenue, despite a noted reduction in operating expenses. The earnings call also emphasized Apellis Pharmaceuticals’ strategic efforts to expand its product line and enhance its market presence. These developments reflect the company’s ongoing commitment to growth and innovation within its sector. Investors may find these updates significant as they evaluate Apellis Pharmaceuticals’ performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.